Literature DB >> 25203009

First PD-1 inhibitor breezes across finish line.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25203009     DOI： 10.1038/nbt0914-847

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Human iPSC and ESC translation potential debated.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2011-05       Impact factor: 54.908

2.  Cautious optimism surrounds early clinical data for PD-1 blocker.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-08       Impact factor: 54.908

3.  Immune-checkpoint inhibitors march on, now in combinations.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-04       Impact factor: 54.908

Review 4.  PD-1 and PD-1 ligands: from discovery to clinical application.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Int Immunol       Date:  2007-07-02       Impact factor: 4.823

Review 5.  Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges.

Authors:  Pramod K Srivastava; Fei Duan
Journal:  Cancer Immunol Immunother       Date:  2013-04-19       Impact factor: 6.968
  5 in total
  2 in total

1.  Keytruda UK's first early-access drug.

Authors: 
Journal:  Nat Biotechnol       Date:  2015-05       Impact factor: 54.908

2.  In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.

Authors:  Asami Nishimori; Satoru Konnai; Tomohiro Okagawa; Naoya Maekawa; Ryoyo Ikebuchi; Shinya Goto; Yamato Sajiki; Yasuhiko Suzuki; Junko Kohara; Satoshi Ogasawara; Yukinari Kato; Shiro Murata; Kazuhiko Ohashi
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.